SOURCE: BurnsAdler Pharmaceuticals, Inc.

January 12, 2007 09:34 ET

BurnsAdler Pharmaceuticals, Inc. and Serral, S.A. de C.V. Enter Into a Promotional Agreement for Gentamicin Surgical Implant

CHARLOTTE, NC -- (MARKET WIRE) -- January 12, 2007 -- BurnsAdler Pharmaceuticals, Inc. ("BurnsAdler") announced today that it has entered into a long-term licensing, promotion and distribution agreement with Serral, S.A. de C.V. ("Serral") to market Garacoll® (gentamicin surgical implant) in Mexico. Garacoll® is a lyophilized collagen sponge impregnated with the amino glycoside antibiotic gentamicin, which is indicated for the prevention and treatment of post-operative and localized tissue infections caused by susceptible bacteria. With more than 50 successfully completed clinical studies and published case reports across a broad range of surgeries in more than 4,900 patients, Garacoll® is the only prescription gentamycin impregnated collagen sponge in the world.

Bryan Somerville, Executive Vice President of BurnsAdler, remarked, "We are pleased to enter into this long-term agreement with Serral, who will help rejuvenate the Garacoll® brand in Mexico. Serral will dedicate a significant hospital sales force to compliment our direct promotional activities in Mexico for Garacoll®. Our effort to relaunch Garacoll® in Mexico is only the first of many marketing initiatives for this breakthrough product throughout Latin America. We expect to complete similar long-term agreements for the Garacoll® brand in Brazil, Argentina, Chile, Colombia and the Dominican Republic during the first half of 2007."

Javier Ramos Suárez, President of Serral, S.A. de C.V., remarked, "We are very satisfied having entered into an agreement with BurnsAdler Pharmaceuticals, Inc. for Garacoll, since this product complements our broad line of Surgical Sutures and our haemostatic product, Quixil. We have arranged to dedicate more than 35% of our total promotional time in the Private Hospitals and the Health Sector to reach the objectives in the Hospitals Division. Additionally, we are convinced that this agreement with BurnsAdler is the beginning of a series of many more agreements."

About Garacoll®

Garacoll® was originally developed by Innocoll, Inc., a privately owned specialty pharmaceutical company, and is based on Innocoll's proprietary collagen CollaRx® (collagen sponge matrix) drug delivery technology. It is approved in over 50 countries worldwide and is marketed under a variety of other trade names in Europe, the Middle East, Africa and Asia. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation in 2005 and has since assumed all sales, marketing and distribution activities for the product through its marketing subsidiary, Innocoll Pharmaceuticals Ltd. BurnsAdler licensed the product for sale in Mexico, Chile, Colombia, Argentina, Brazil and the Dominican Republic as well as select Caribbean islands from Innocoll Pharmaceuticals in August 2006.

About Serral, S.A. de C.V.

With their headquarters located in Mexico City, Serral is a local pharmaceutical company that has developed, manufactured, commercialized and marketed pharmaceutical products since 1948. Currently Serral has over 500 employees of which 100 are in direct contact with their clients. Serral has six pharmaceutical divisions with over 100 different pharmaceutical products ranging from brand named to generic products.

About BurnsAdler Pharmaceuticals, Inc.

BurnsAdler creates long-term, exclusive agreements, which grant the right to license, supply and market products wherever their partners are interested in generating additional revenue and profit. The company focuses on promoting products in South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler's portfolio currently includes products targeted for the cardiovascular, orthopedic, oncology, CNS and critical care markets.

For additional information about this news release contact Maryori Oyola at +1.704.552-8410 Ext. 231. Find additional information about BurnsAdler at

Contact Information

  • BurnsAdler Contact
    Ms. Maryori Oyola
    Marketing Associate
    +1.704.552.8410 (phone) Ext. 231
    +1.704.552.8411 (fax)
    Email Contact